Needle Free Injections Clinical Trial Analysis

Summary

Global Markets Direct's "Needle Free Injections Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Needle Free Injections manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Needle Free Injections market categories - Needle Free Injections
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Needle Free Injections market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Needle Free Injections Clinical Trials
  • 2.1 Needle Free Injections Clinical Trial By Equipment Type
  • 2.2 Needle Free Injections Clinical Trials By Trial Phase and Trial Status
  • 2.3 Needle Free Injections Pipeline Products By Development Stage
  • 2.4 Needle Free Injections Pipeline Products By Therapy Area
  • 2.5 Needle Free Injections Pipeline Products By News Summary
  • 2.6 Needle Free Injections Intradermal Syringe
    • 2.6.1 Clinical Trial Of Safety (Reactogenicity) And Immunogenicity Of Needle-Free Jet Injection Of Reduced-Dose, Intradermal Influenza Vaccine (INF) Administered To >= 6 to < 24 Month-Old Infants And Toddlers In The Dominican Republic
  • 2.7 Needle Free Injections Smart Patch delivery system for Fertility Hormone
    • 2.7.1 Non-Invasive Delivery Of Peptide Using Smart Patch Technology
  • 2.8 Needle Free Injections sumatriptan DosePro
    • 2.8.1 A Multi-Center, Open-Label, Single-Dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject System in Adult Patients During Acute Migraine Attack
  • 2.9 Needle Free Injections ViaDerm-hPTH
    • 2.9.1 A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) in Comparison to Subcutaneous Injection of Forteo in Postmenopausal Women With Osteoporosis
  • 2.10 Needle Free Injections ViaDerm-hGH
    • 2.10.1 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study, to Assess Tolerability, Safety, Pharmacokinetic and Pharmacodynamic Profiles of hGH-ViaDerm System in Adult Subjects With Growth Hormone Deficiency
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 Apr 04, 2009: Bioject Medical Technologies Receives US FDA Approval To Market Zetajet Needle-Free Injection Therapy System
    • 3.1.2 Mar 10, 2009: Vyteris Announces Phase II Clinical Trial Commencement Of Smart Patch Technology For Infertility Treatment
    • 3.1.3 Feb 24, 2009: Bioject Medical Announces Collaborative Research Agreement With IAVI
    • 3.1.4 Jan 02, 2007: CT Exprs III Receives FDA clearance
  • 3.2 Product Approvals
    • 3.2.1 Apr 04, 2009: Bioject Medical Technologies Receives US FDA Approval To Market Zetajet Needle-Free Injection Therapy System
  • 3.3 Clinical Trials
    • 3.3.1 Mar 10, 2009: Vyteris Announces Phase II Clinical Trial Commencement Of Smart Patch Technology For Infertility Treatment
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Needle Free Injections Clinical Trial By Equipment Type
  • Table 2: Needle Free Injections Clinical Trials By Trial Phase and Trial Status
  • Table 3: Needle Free Injections Pipeline Products By Development Stage
  • Table 4: Needle Free Injections Pipeline Products By Therapy Area
  • Table 5: Needle Free Injections Pipeline Products By News Summary
  • Table 6: Intradermal Syringe - Clinical Trial Of Safety (Reactogenicity) And Immunogenicity Of Needle-Free Jet Injection Of Reduced-Dose, Intradermal Influenza Vaccine (INF) Administered To >= 6 to < 24 Month-Old Infants And Toddlers In The Dominican Republic
  • Table 7: Smart Patch delivery system for Fertility Hormone - Non-Invasive Delivery Of Peptide Using Smart Patch Technology
  • Table 8: sumatriptan DosePro - A Multi-Center, Open-Label, Single-Dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject System in Adult Patients During Acute Migraine Attack
  • Table 9: ViaDerm-hPTH 1-34 - A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) in Comparison to Subcutaneous Injection of Forteo in Postmenopausal Women With Osteoporosis
  • Table 10: ViaDerm-hGH - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study, to Assess Tolerability, Safety, Pharmacokinetic and Pharmacodynamic Profiles of hGH-ViaDerm System in Adult Subjects With Growth Hormone Deficiency
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology